Both are pharmacologically active compounds with documented effects on the cardiovascular system, the gastrointestinal tract, and metabolic regulation
Every day, the Today tab is where you record how you are doing
Tirzepatide, a dual GLP-1 and GIP receptor agonist, has a half-life closer to 5 days, placing it between weekly injectables and daily oral formulations in terms of duration
"The lowest dose is almost never the dose that people wind up being on," said Korner
Animal studies have also shown that portal vein GLP-1 weakens intestinal fat absorption and chylomicron production through the vagal enteric-brain-liver axis, and reduces postprandish and fasting blood lipids [79]
These alternatives are designed to provide sustainable, long-term results whilst minimising health risks